Sutro Biopharma (STRO) Operating Income (2017 - 2025)
Historic Operating Income for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to -$48.5 million.
- Sutro Biopharma's Operating Income rose 2865.18% to -$48.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$185.6 million, marking a year-over-year decrease of 4270.36%. This contributed to the annual value of -$238.5 million for FY2024, which is 16709.04% down from last year.
- According to the latest figures from Q3 2025, Sutro Biopharma's Operating Income is -$48.5 million, which was up 2865.18% from -$3.3 million recorded in Q2 2025.
- Over the past 5 years, Sutro Biopharma's Operating Income peaked at $43.2 million during Q4 2023, and registered a low of -$68.5 million during Q1 2025.
- In the last 5 years, Sutro Biopharma's Operating Income had a median value of -$42.2 million in 2023 and averaged -$35.6 million.
- In the last 5 years, Sutro Biopharma's Operating Income skyrocketed by 18766.81% in 2023 and then tumbled by 25122.82% in 2024.
- Sutro Biopharma's Operating Income (Quarter) stood at -$35.0 million in 2021, then plummeted by 40.49% to -$49.2 million in 2022, then surged by 187.67% to $43.2 million in 2023, then plummeted by 251.23% to -$65.3 million in 2024, then rose by 25.74% to -$48.5 million in 2025.
- Its Operating Income stands at -$48.5 million for Q3 2025, versus -$3.3 million for Q2 2025 and -$68.5 million for Q1 2025.